The Europe Dystonia Drugs Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).
Two or more contiguous or close-proximity body parts are affected by segmental dystonia. Up to 30% of individuals with focal dystonia experience spasms in regions close to the primary location. A prevalent form of segmental dystonia affects the lower face, jaw, and eyelids. Different varieties of dystonia include multifocal, which involves two or more distant body parts, and hemidystonia, which affects half the body. And generalized, which typically begins in the legs and then extends to one or more body areas.
Primary (idiopathic) dystonia is the only symptom, and other causes have been ruled out. Most primary dystonia are varied, manifest in adults, and are focal or segmental in origin. Yet, specific childhood or adolescent-onset primary dystonia have been associated with genetic alterations. DYT1 gene mutations cause most childhood or early adulthood-onset primary dystonia. This gene has been located at 9q34.1 on the long arm of chromosome 9. In 90 to 95% of cases, symptoms begin in a limb before spreading to other body areas. This dystonia typically manifests itself between the ages of 12 and 29.
Germany's healthcare system is robust in terms of facilities, hospital beds, and qualified personnel. In Germany, one in six employees is related to the healthcare industry, which has an economic impact of EUR 678.2 billion (USD 798 billion), or nearly 12% of Germany's GDP. HCT contributes 8.3% of Germany's overall exports, or EUR 131.2 billion (USD 154.4 billion), through foreign sales. The German medical equipment industry will grow at a compound annual growth rate of 5.1 percent in euro terms and 6.8 percent in US dollar terms between 2020 and 2025. The presence of a robust healthcare system, joined with the increased spending, will aid in the development of dystonia drugs and their usage thereby driving the market growth in the Europe region.
The Germany market dominated the Europe Dystonia Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $77.3 Million by 2028. The UK market is anticipated to grow at a CAGR of 4.3% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 6% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Type, the market is segmented into GABAergic Agents, Dopaminergic Agents, Anticonvulsants Drugs and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Dystonia Drugs Market will Hit $1.1 Billion by 2028, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), Amneal Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, and Wellona Pharma.
By Distribution Channel
By Route of Administration
By Type
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 